Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Bio Medica Laboratories IPO
Price Band
₹132.0–139.0
Issue Size
₹52.43 Cr
Lot Size
1,000 shares
Min Investment
₹278,000
2 LOTS MIN
GMP
₹-9.0 (-6.47%)
Issue Price
₹139.0
Bio Medica Laboratories IPO AI Summary
- Bio Medica Laboratories IPO is listed on NSE SME in the Pharmaceuticals sector.
- Price band: ₹132.0–₹139.0 per share, lot size 1,000 shares (min. investment ₹278,000, 2 lots minimum).
- Subscription window: 21 May–25 May 2026, listing on 29 May 2026.
- Current GMP is ₹-9.0 (-6.47%), an estimated listing price of ₹130 — unofficial and can change daily.
Bio Medica Laboratories is an SME in the pharmaceuticals sector, focused on injectable products for healthcare. With a diverse product portfolio and strong regulatory compliance, the company aims to enhance its production capabilities through the IPO proceeds. Investors should consider the potential risks and rewards associated with this offering.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Bio Medica Laboratories IPO Grey Market Premium (GMP) Today
GMP
₹-9.0
GMP %
-6.47%
Est. Listing
₹130.0
Updated: 14 Jul 2026 15:51
About the Company
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, with a focus on liquid and dry powder injectables for both human and veterinary healthcare applications. The company produces a broad range of ethical medicines, generic formulations, and over-the-counter (OTC) pharmaceutical products. Its injectable products are manufactured in both single-dose and multi-dose formats to cater to diverse therapeutic and clinical requirements. Product portfolio: Liquid Injectables – 58 products Dry Powder Injectables – 15 products The company offers a diversified pharmaceutical portfolio comprising generic medicines, branded formulations, OTC products, and other injectable medications across multiple therapeutic categories. Bio Medica Laboratories primarily operates under a B2B contract manufacturing model, developing and manufacturing formulations for pharmaceutical companies based on their specific product requirements and technical specifications. The company holds certifications for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), issued by the Food & Drugs Administration, Madhya Pradesh, reflecting its focus on quality and regulatory compliance. It operates through two manufacturing facilities located in Indore, Madhya Pradesh. Competitive strengths: Multi-product manufacturing capabilities with a diversified injectable portfolio. Experienced promoters, management team, and skilled workforce. Strong quality assurance processes supported by regulatory certifications. Established long-term relationships with customers in the pharmaceutical industry.
Company Financials (₹ Cr)
As of 2025-11-30
| Period Ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Key Ratios
EPS
₹10.67
NAV
₹16.05
ROE
99.59%
ROCE
48.20%
RoNW
99.59%
P/B Value
8.66
P/E Ratio
13.03
Market Cap
₹174.79 Cr
PAT Margin
25.64%
Debt/Equity
1.02
Promoters
Mukesh Mehta and Pradeep Mehta
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Repayment of loan 6.50 2 Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises 28.50 3 General Corporate Purposes 7.05 4 Issue Expense 5.14 Total 47.19
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹16.25 Cr in the year ending 31 Mar 2023, rising to ₹15.34 Cr by 31 Mar 2024. This increased to ₹38.33 Cr in the year ending 31 Mar 2025, though this is a 9-month figure, not a full year, so isn't directly comparable. Most recently, total income was ₹28.63 Cr as of 30 Nov 2025.
Profit Trend
Profit after tax was ₹0.33 Cr in the year ending 31 Mar 2023, increasing to ₹2.50 Cr by 31 Mar 2024. It further rose to ₹9.79 Cr in the year ending 31 Mar 2025, though this is a 9-month figure, not a full year, so isn't directly comparable. Most recently, profit after tax was ₹8.66 Cr as of 30 Nov 2025.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the potential premium at which an IPO might list on the stock exchange compared to its issue price. A positive GMP suggests strong demand, while a negative GMP indicates weaker demand. Investors should consider GMP as one of many factors when evaluating an IPO.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against the company's fundamentals, growth potential, and market conditions. It's important to assess how the company's business model aligns with your investment strategy.
Who May Want to Wait
Investors who prefer stable, established companies with predictable earnings may want to avoid this IPO, as it operates in a competitive sector and is subject to market fluctuations and regulatory changes.
IPO Timeline, Explained
The IPO process includes several key dates: the issue opens on 21 May 2026 and closes on 25 May 2026. Allotment of shares will be finalized by 26 May 2026, with the listing date set for 29 May 2026.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor might make if they sell their shares on the listing day at a price higher than the issue price. However, these gains are not guaranteed and can be influenced by market conditions, investor sentiment, and the company's performance post-listing. Investors should be aware of the risks involved in relying on listing-day gains.
This evaluation is generated from Bio Medica Laboratories's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Bio Medica Laboratories IPO GMP today?
Bio Medica Laboratories IPO GMP today is ₹-9.0 (-6.47%), indicating an estimated listing price of ₹130. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Bio Medica Laboratories IPO?
The price band of Bio Medica Laboratories IPO is ₹132.0–₹139.0 per share.
When does Bio Medica Laboratories IPO open and close?
Bio Medica Laboratories IPO opens on 21 May 2026 and closes on 25 May 2026.
When does Bio Medica Laboratories IPO list on the stock exchange?
Bio Medica Laboratories IPO listed on 29 May 2026 at ₹130.0.
What is the lot size for Bio Medica Laboratories IPO?
The lot size for Bio Medica Laboratories IPO is 1000 shares, requiring a minimum investment of ₹278,000 (2 lots).
What is the price band for the IPO?
The price band for the IPO is ₹132.0 to ₹139.0.
What is the minimum investment required?
The minimum investment required is ₹278,000.
What is the lot size for the IPO?
The lot size for the IPO is 1000 shares.
When is the listing date?
The listing date is scheduled for 29 May 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium at which the IPO might list compared to its issue price.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
21 May 2026
Close
25 May 2026
Allotment
26 May 2026
Listing
29 May 2026
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Bio Medica Laboratories?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.